Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4506)	6/17/1998 11:36:00 AM
From: Steve Fancy	Read Replies (2) of 6136

Immune Response Corp Begins Clinical Trial Of HIV Drug Dow Jones Newswires CARLSBAD, Calif. -- Immune Response Corp. (IMNR) began a double-blind, placebo-controlled clinical trial of Remune, an HIV drug. Immune Response and Agouron Pharmaceuticals Inc. (AGPH) are developing Remune. In a press release Wednesday, the company said the one-year trial will test the drug's effect on HIV-specific immune responses in HIV-1 patients who have been treated with highly active antiretroviral therapy, or HAART. The company will enroll HIV-infected patients who have undetectable viral load after taking HAART for at least six months. It will treat the patients with Remune or the placebo in combination with HAART. According to Immune Response, scientists conducting the trial previously have shown a correlation between HIV-specific T-cell proliferation and the successful control of virus replication in certain HIV patients. The trial will examine whether inducement of such immune responses can be increased in Remune-treated individuals who are taking HAART as well.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next